HLB Pharmaceutical Co. Ltd (047920) — Capital Reinvestment Ratio
HLB Pharmaceutical Co. Ltd (047920) has a Capital Reinvestment Ratio of 1.21x as of September 2025, meaning it reinvests 1% of its operating cash flow (₩1.86 Billion) in capital expenditures (₩2.26 Billion). Check HLB Pharmaceutical Co. Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
HLB Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks HLB Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see 047920 cash flow conversion.
Annual Capital Reinvestment Ratio for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for HLB Pharmaceutical Co. Ltd from 2014 to 2024. See 047920 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.45x | ₩6.84 Billion | ₩3.09 Billion | ▼ -56.2% |
| 2019 | 1.03x | ₩1.35 Billion | ₩1.40 Billion | ▼ -29.6% |
| 2014 | 1.47x | ₩1.54 Billion | ₩2.26 Billion | — |